Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Temporal scRNAseq identifies dynamic transcriptional programs that dictate the outcome of ER stress

ABSTRACT: Temporal scRNAseq identifies dynamic transcriptional programs that dictate the outcome of ER stress

PROVIDER: PRJNA629494 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11652417.fastq.gz	Fastqsanger.gz
	SRR11652418.fastq.gz	Fastqsanger.gz
	SRR11652419.fastq.gz	Fastqsanger.gz
	SRR11652420.fastq.gz	Fastqsanger.gz
	SRR11652421.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Temporal scRNAseq identifies dynamic transcriptional programs that dictate the outcome of ER stress

Project description:Perturbation of tissue homeostasis accompanies a diversity of inflammatory pathologies and imposes metabolic constraints at the cellular level that elicit ER stress, protein misfolding, and cell death. In response to ER stress, cells initiate the unfolded protein response (UPR), which determines divergent cell fate decisions, either promoting recovery of ER proteostasis and cell survival or triggering programmed cell death. However, the mechanisms by which the UPR transitions from the adaptive to terminal state are not fully understood. Here, we leverage single-cell genomics to define dynamic transcriptional states associated with the adaptive versus terminal UPR in the intestinal epithelium. We recovered the terminal-UPR signature, which dictates adaptation versus programmed cell death in response to ER stress.

2021-02-17 | GSE149633 | GEO

Calponin 2 regulates ketogenesis to dictate the outcome of acute kidney injury

Project description:Calponin 2 regulates ketogenesis to dictate the outcome of acute kidney injury

| PRJNA940494 | ENA

GR and ER co-activation alters the expression of differentiation genes and associates with improved ER+ breast cancer outcome

Project description:Analysis of MCF-7 cells treated for 4h with Ethanol, Estradiol (E2), Dexamethasone (Dex), or Estradiol + Dexamethasone (E2 + Dex) In estrogen receptor (ER)-negative breast cancer (BC), high tumor glucocorticoid receptor (GR) expression has been associated with a relatively poor outcome. In contrast, using a meta-analysis of several genomic datasets, here we find that tumor GR mRNA expression is associated with improved ER+ relapse-free survival (RFS) (independently of progesterone receptor (PR) expression). To understand the mechanism by which GR expression is associated with a better ER+ BC outcome, the global effect of GR-mediated transcriptional activation in ER+ BC cells was studied. Analysis of GR chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) in ER+/GR+ MCF-7 cells revealed that upon co-activation of GR and ER, GR chromatin association became enriched at proximal promoter regions. Furthermore, following ER activation, increased association of GR was observed at ER, FOXO, and AP1 response elements. In addition, it was determined that ER associated with GR response elements, suggesting that ER and GR interact in a complex. Co-activation of GR and ER resulted in increased expression (relative to ER activation alone) of transcripts that encode proteins promoting cellular differentiation (e.g. KDM4B, VDR) and inhibiting Wnt-signaling (IGFBP4). Finally, expression of these individual pro-differentiation genes was associated with significantly improved RFS in ER+ BC patients. Together, these data demonstrate that the co-expression and subsequent activity of tumor cell GR and ER contribute to the less aggressive natural history of early-stage BC by coordinating the altered expression of genes favoring differentiation. Four treatment samples (Vehicle V, Dex D, E2, or Dex+E2). Three biological replicate experiments per sample. Vehicle sample is Ethanol control.

2016-04-01 | E-GEOD-79761 | biostudies-arrayexpress

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

Project description:Oestrogen receptor-a (ER) is the defining and driving transcrip- tion factor in the majority of breast cancers and its target genes dictate cell growth and endocrine response, yet genomic under- standing of ER function has been restricted to model systems13. Here we map genome-wide ER-binding events, by chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq), in primary breast cancers from patients with different clinical outcomes and in distant ER-positive metastases. We find that drug-resistant cancers still recruit ER to the chromatin, but that ER binding is a dynamic process, with the acquisition of unique ER-binding regions in tumours from patients that are likely to relapse. The acquired ER regulatory regions associated with poor clinical outcome observed in primary tumours reveal gene signatures that predict clinical outcome in ER-positive disease exclusively. We find that the differential ER-binding programme observed in tumours from patients with poor outcome is not due to the selection of a rare subpopulation of cells, but is due to the FOXA1-mediated reprogramming of ER binding on a rapid time- scale. The parallel redistribution of ER and FOXA1 cis-regulatory elements in drug-resistant cellular contexts is supported by histological co-expression of ER and FOXA1 in metastatic samples. By establishing transcription-factor mapping in primary tumour material, we show that there is plasticity in ER-binding capacity, with distinct combinations of cis-regulatory elements linked with the different clinical outcomes.

2012-01-04 | GSE32222 | GEO

GR and ER co-activation alters the expression of differentiation genes and associates with improved ER+ breast cancer outcome

2016-04-01 | GSE79761 | GEO

Ependymoma subpopulation lineages underlie clinical classification and outcome (scRNAseq data set)

Project description:Ependymoma subpopulation lineages underlie clinical classification and outcome (scRNAseq data set)

| PRJNA518131 | ENA

Interferon-gamma is Quintessential for NOS2 and COX2 Expression in ER- Breast Tumors that Lead to Poor Outcome

Project description:Previously, we have proved the NOS2 and COX2 genes play an important role in ER-negative breast cancer. In this study, we utilized the scRNAseq technique to investigate how cancer cells react to cytokines with and without IFNG combination treatments.

2023-12-31 | GSE232567 | GEO

Identification of a novel ER-NFκB driven stem-like cell population associated with poor outcome of ER+ breast cancer patients

Project description:Up to 40% of patients with Estrogen Receptor positive (ER+) breast cancer experience relapse. Breast cancer stem cells (BCSCs) are known to be involved in therapy resistance, relapse, and development of more aggressive and metastatic tumors. Therefore, there is an urgent need to identify genes/pathways that drive stem-like cell properties in ER+ breast tumors. Using single-cell RNA sequencing and bioinformatic approaches, with additional follow-up studies, we identified a unique quiescent stem-like cell population that is driven by ER and NFkB in multiple ER+ breast cancer models. Moreover, a gene signature derived from this stem-like population is expressed in endocrine therapy-resistant and metastatic cell populations and predictive of poor patient outcome. These findings indicate a novel role for ER and NFkB crosstalk in BCSCs biology and understanding the mechanism by which these pathways promote stem properties may be exploited to improve outcomes for ER+ breast cancer patients at risk of relapse.

2022-12-16 | GSE205415 | GEO

QRICH1 Dictates the Outcome of ER Stress through Transcriptional Control of Proteostasis

Project description:QRICH1 Dictates the Outcome of ER Stress through Transcriptional Control of Proteostasis

| PRJNA612072 | ENA

Identification of a novel ER-NFκB driven stem-like cell population associated with poor outcome of ER+ breast cancer patients

Project description:Identification of a novel ER-NFκB driven stem-like cell population associated with poor outcome of ER+ breast cancer patients

| PRJNA844988 | ENA